Showing results (81-90 of 119) with videos related to

Sort By:
Pageof 12
BJU International|May 27, 2018
Matrix metalloproteinase 7, soluble Fas and Fas ligand serum levels for predicting docetaxel resistance and survival in castration-resistant prostate cancerTibor Szarvas, Sabina Sevcenco, Orsolya Módos, et al.
European Urology Focus|May 16, 2025
Prostate-specific Antigen Response as a Prognostic Factor for Overall Survival in Patients with Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors: A Systematic Review and Meta-analysisMarcin Miszczyk, Tamás Fazekas, Paweł Rajwa, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 25, 2021
177Lu-Prostate-Specific Membrane Antigen Ligand After 223Ra Treatment in Men with Bone-Metastatic Castration-Resistant Prostate Cancer: Real-World Clinical ExperienceOliver Sartor, Christian la Fougère, Markus Essler, et al.
The Journal of Urology|June 20, 2023
Efficacy of Systemic Treatment in Prostate Cancer Patients With Visceral Metastasis: A Systematic Review, Meta-analysis, and Network Meta-analysisTakafumi Yanagisawa, Pawel Rajwa, Tatsushi Kawada, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 19, 2025
Does PARP1 up-regulation correlate with PSMA expression in patients with metastatic castration-resistant prostate cancer studied with [18F]PARPi and [68Ga]PSMA PET/CT?Holger Einspieler, Heidemarie Ofner, Marius Ozenil, et al.
Prostate Cancer and Prostatic Diseases|November 21, 2019
Assessment of body composition in the advanced stage of castration-resistant prostate cancer: special focus on sarcopeniaJudith Stangl-Kremser, Rodrigo Suarez-Ibarrola, David D' Andrea, et al.
Cancers|April 27, 2024
Assessment of PSMA Expression of Healthy Organs in Different Stages of Prostate Cancer Using [68Ga]Ga-PSMA-11-PET ExaminationsHolger Einspieler, Kilian Kluge, David Haberl, et al.
Targeted Oncology|April 7, 2021
Real-World Safety and Efficacy Outcomes with Abiraterone Acetate Plus Prednisone or Prednisolone as the First- or Second-Line Treatment for Metastatic Castration-Resistant Prostate Cancer: Data from the Prostate Cancer RegistryAnders Bjartell, Nicolaas Lumen, Pablo Maroto, et al.
The Prostate|October 16, 2019
Response assessment using [68 Ga]Ga-PSMA ligand PET in patients undergoing systemic therapy for metastatic castration-resistant prostate cancerBernhard Grubmüller, Sazan Rasul, Pascal Baltzer, et al.
Targeted Oncology|June 6, 2020
Real-World Outcomes in First-Line Treatment of Metastatic Castration-Resistant Prostate Cancer: The Prostate Cancer RegistrySimon Chowdhury, Anders Bjartell, Nicolaas Lumen, et al.
Pageof 12